Short Interest in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Drops By 23.8%

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) saw a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 6,400 shares, a decline of 23.8% from the July 15th total of 8,400 shares. Based on an average trading volume of 13,700 shares, the short-interest ratio is presently 0.5 days.

Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. acquired a new stake in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 980 shares of the company’s stock, valued at approximately $25,000. Institutional investors and hedge funds own 2.83% of the company’s stock.

Calliditas Therapeutics AB (publ) Trading Down 1.0 %

Calliditas Therapeutics AB (publ) stock traded down $0.41 during midday trading on Thursday, hitting $38.80. 39,867 shares of the stock were exchanged, compared to its average volume of 10,220. Calliditas Therapeutics AB has a 52 week low of $15.25 and a 52 week high of $41.90. The stock has a market capitalization of $1.16 billion, a PE ratio of -21.19 and a beta of 1.77. The company has a quick ratio of 2.62, a current ratio of 2.69 and a debt-to-equity ratio of 8.46. The company has a fifty day simple moving average of $38.98 and a two-hundred day simple moving average of $28.18.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last posted its earnings results on Tuesday, August 13th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.09. Calliditas Therapeutics AB (publ) had a negative return on equity of 160.87% and a negative net margin of 40.19%. The firm had revenue of $52.36 million for the quarter, compared to analyst estimates of $42.89 million. During the same period in the previous year, the company posted ($0.33) earnings per share. Equities research analysts anticipate that Calliditas Therapeutics AB will post -0.86 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on CALT shares. Citigroup restated a “neutral” rating and set a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a research report on Friday, May 31st. Jefferies Financial Group reissued a “hold” rating and issued a $39.00 target price (down from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Lifesci Capital downgraded shares of Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 28th. HC Wainwright restated a “neutral” rating and issued a $39.00 price objective on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $40.00 target price (down previously from $55.00) on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. Six research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $35.00.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.